1. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58:e44–100.
Article
2. Shildt RA, Boyd JF, McCracken JD, Schiffman G, Giolma JP. Antibody response to pneumococcal vaccine in patients with solid tumors and lymphomas. Med Pediatr Oncol. 1983; 11:305–9.
Article
3. Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol. 2002; 19:71–8.
4. Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB, Ryan AL, et al. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients. Cancer. 2017; 123:4215–23.
Article
5. Wumkes ML, van der Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 2013; 31:6177–84.
Article
6. Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, et al. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013; 31:4765–74.
Article
7. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016; 4:399–406.
Article
8. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013; 28:4–15.
Article
9. Song JY, Cheong HJ, Tsai TF, Chang HA, Choi MJ, Jeon JH, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine. 2015; 33:4647–52.
Article
10. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006; 13:1004–9.
Article
11. Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res. 2004; 103:125–32.
Article
12. Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013; 19:412–25.
Article
13. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999; 29:281–8.
Article
14. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003; 187:1639–45.
Article
15. Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect. 2013; 19 Suppl 1:1–9.
Article
16. Addiego JE Jr, Ammann AJ, Schiffman G, Baehner R, Higgins G, Hammond D. Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease: Children's Cancer Study Group Report. Lancet. 1980; 2:450–2.
17. Frederiksen B, Specht L, Henrichsen J, Pedersen FK, Pedersen-Bjergaard J. Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. Eur J Haematol. 1989; 43:45–9.
Article
18. Sinisalo M, Vilpo J, Itala M, Vakevainen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007; 26:82–7.
Article